Literature DB >> 18528419

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype.

C Haferlach1, F Dicker, H Herholz, S Schnittger, W Kern, T Haferlach.   

Abstract

In acute myeloid leukemia (AML) with complex aberrant karyotype, a loss of one TP53 allele is frequently observed. We analyzed the incidence of TP53 mutations and deletions in 107 AML with complex aberrant karyotype. In 50 of 57 cases showing a loss of one TP53 allele, a TP53 mutation was detected in the remaining allele. In addition, in 33 of 50 cases with two TP53 copies, a TP53 mutation was found. Therefore, the frequency of TP53 mutations in AML with complex aberrant karyotype was 78%. In a second step, we analyzed TP53 mutations in a cohort of AML comprising different cytogenetic subgroups. TP53 mutations were detected in 33 of 235 cases (14%). Coincidences with other molecular mutations were rare. We confirmed a high incidence of TP53 mutations in AML with a complex aberrant karyotype (29/42, 69%) and demonstrated that TP53 mutations are very rare in AML without a complex aberrant karyotype (4/193, 2.1%).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18528419     DOI: 10.1038/leu.2008.143

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  72 in total

1.  Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.

Authors:  Brian Parkin; Harry Erba; Peter Ouillette; Diane Roulston; Anjali Purkayastha; Judith Karp; Moshe Talpaz; Lisa Kujawski; Sajid Shakhan; Cheng Li; Kerby Shedden; Sami N Malek
Journal:  Blood       Date:  2010-08-20       Impact factor: 22.113

2.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 3.  Next-generation sequencing-based panel testing for myeloid neoplasms.

Authors:  Frank C Kuo; Fei Dong
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

4.  CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

Authors:  Leena Chaudhuri; Nicole D Vincelette; Brian D Koh; Ryan M Naylor; Karen S Flatten; Kevin L Peterson; Amanda McNally; Ivana Gojo; Judith E Karp; Ruben A Mesa; Lisa O Sproat; James M Bogenberger; Scott H Kaufmann; Raoul Tibes
Journal:  Haematologica       Date:  2013-10-31       Impact factor: 9.941

5.  HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.

Authors:  Jing Qi; Sandeep Singh; Wei-Kai Hua; Qi Cai; Shi-Wei Chao; Ling Li; Hongjun Liu; Yinwei Ho; Tinisha McDonald; Allen Lin; Guido Marcucci; Ravi Bhatia; Wei-Jan Huang; Chung-I Chang; Ya-Huei Kuo
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

6.  Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia.

Authors:  Christopher J Walker; Jessica Kohlschmidt; Ann-Kathrin Eisfeld; Krzysztof Mrózek; Sandya Liyanarachchi; Chi Song; Deedra Nicolet; James S Blachly; Marius Bill; Dimitrios Papaioannou; Christopher C Oakes; Brian Giacopelli; Luke K Genutis; Sophia E Maharry; Shelley Orwick; Kellie J Archer; Bayard L Powell; Jonathan E Kolitz; Geoffrey L Uy; Eunice S Wang; Andrew J Carroll; Richard M Stone; John C Byrd; Albert de la Chapelle; Clara D Bloomfield
Journal:  Clin Cancer Res       Date:  2019-08-02       Impact factor: 12.531

7.  Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

Authors:  Hideki Makishima; Heather Cazzolli; Hadrian Szpurka; Andrew Dunbar; Ramon Tiu; Jungwon Huh; Hideki Muramatsu; Christine O'Keefe; Eric Hsi; Ronald L Paquette; Seiji Kojima; Alan F List; Mikkael A Sekeres; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

8.  Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.

Authors:  Aziz Nazha; Hagop M Kantarjian; Vijaya R Bhatt; Graciela Nogueras-Gonzalez; Jorge E Cortes; Tapan Kadia; Guillermo Garcia-Manero; Lynne Abruzzo; Naval Daver; Naveen Pemmaraju; Alfonso Quintas-Cardama; Farhad Ravandi; Michael Keating; Gautam Borthakur
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-01-22

Review 9.  Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.

Authors:  Michael Medinger; Claudia Lengerke; Jakob Passweg
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

Review 10.  The use of molecular genetics to refine prognosis in acute myeloid leukemia.

Authors:  Bhavana Bhatnagar; Ramiro Garzon
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.